{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:24:27Z","timestamp":1754151867432,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Due to a lack of studies on the relationship between vancomycin trough concentration and clinical outcomes in pediatric patients, there is insufficient evidence to provide a unified standard for vancomycin trough concentration for children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed the data of drug-resistant Gram-positive bacteria isolated from human germfree samples of 66 children diagnosed as definite infectious diseases. Vancomycin was intravenously delivered and the trough concentration was monitored regularly. Receiver operator characteristic curve (ROC curve) was used to explore the relationship between vancomycin trough concentration and treatment outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>40.9% of the enrolled pediatric patients had poor outcomes. A vancomycin trough concentration above 6.8\u2005mg\/L (OR\u2009=\u20090.014, 95% confidence interval 0.001\u20130.351, <jats:italic>P<\/jats:italic>\u2009=\u20090.009) was identified as an independent protective factor, while trough concentrations above 10\u2005mg\/L appeared to be necessary to support favorable outcomes within 4 days of treatment in children with secondary bloodstream infections and non-bloodstream infections. 4 (6.35%) patients displayed vancomycin-related acute kidney injury (AKI) with an average trough concentration of 10.85\u2005mg\/L, and 50% of them simultaneously used nephrotoxic drugs. Moreover, within 7 days of vancomycin administration, there was a significant decrease in serum creatinine and an increase in creatinine clearance rate, and the children with augmented renal clearance exhibited significantly lower vancomycin trough concentrations and higher proportion of poor outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A vancomycin trough concentration above 6.8\u2005mg\/L is sufficient to support favorable outcomes in children who were infected with drug-resistant Gram-positive bacteria. Compared with vancomycin-associated AKI, augmented renal clearance and subsequent poor antibiotic treatment outcome deserve more attention.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1597306","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T06:06:08Z","timestamp":1753077968000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world study of the optimal cut-off value for vancomycin trough concentration associated with outcomes in children infected with drug-resistant Gram-positive bacteria"],"prefix":"10.3389","volume":"13","author":[{"given":"Yinghui","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengjiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/cid\/ciaa1536","article-title":"Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese pharmacological society","volume":"71","author":"He","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the American society of health-system pharmacists, and the society of infectious diseases pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e01293","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an academic medical center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jpids\/piz036","article-title":"Intravenous vancomycin therapeutic drug monitoring in children: evaluation of a pharmacy-driven protocol and collaborative practice agreement","volume":"9","author":"Olson","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2147\/RMHP.S244836","article-title":"Vancomycin dosage and its association with clinical outcomes in pediatric patients with gram-positive bacterial infections","volume":"13","author":"Shin","year":"2020","journal-title":"Risk Manag Healthc Policy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3760\/cma.j.issn.0578-1310.2009.07.004","article-title":"Growth curves of body mass index for Chinese children and adolescents aged 0-18 years","volume":"47","author":"Li","year":"2009","journal-title":"Chin J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3760\/cma.j.cn112140-20230925-00219","article-title":"Revision of growth standards for Chinese children under 7 years of age","volume":"61","author":"Zong","year":"2023","journal-title":"Chin J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1055\/a-2251-5686","article-title":"[WHO recommendations for care of the preterm or low-birth-weight infant]","volume":"86","author":"Ledinger","year":"2024","journal-title":"Gesundheitswesen"},{"key":"B12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","article-title":"Bloodstream infections in critically ill patients: an expert statement","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"B14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: a systematic review","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1373\/clinchem.2007.099648","article-title":"Reference intervals for serum creatinine concentrations: assessment of available data for global application","volume":"54","author":"Ceriotti","year":"2008","journal-title":"Clin Chem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0013822","DOI":"10.1128\/aac.00138-22","article-title":"Relationship between vancomycin trough serum concentrations and clinical outcomes in children: a systematic review and meta-analysis","volume":"66","author":"Cao","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"106393","DOI":"10.1016\/j.ijantimicag.2021.106393","article-title":"Systematic review and meta-analysis to explore optimal therapeutic range of vancomycin trough level for infected paediatric patients with gram-positive pathogens to reduce mortality and nephrotoxicity risk","volume":"58","author":"Kato","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"B20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/s12887-023-04288-4","article-title":"Age-associated augmented renal clearance and low BMI trigger suboptimal vancomycin trough concentrations in children with haematologic diseases: data of 1453 paediatric patients from 2017 to 2022","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.2215\/CJN.05920616","article-title":"Vancomycin and the risk of AKI: a systematic review and meta-analysis","volume":"11","author":"Sinha Ray","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"723731","DOI":"10.3389\/fphar.2021.723731","article-title":"Augmented renal clearance: what have we known and what will we do","volume":"12","author":"Luo","year":"2021","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00467-019-04205-x","article-title":"Augmented renal clearance: a common condition in critically ill children","volume":"34","author":"Van Der Heggen","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jcrc.2013.03.003","article-title":"Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy","volume":"28","author":"Claus","year":"2013","journal-title":"J Crit Care"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1597306\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T06:06:10Z","timestamp":1753077970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1597306\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":25,"alternative-id":["10.3389\/fped.2025.1597306"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1597306","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"article-number":"1597306"}}